Motion Acquisition Corp.

The filer is the post-combination operating company, not a blank-check shell: there is no trust account, no redemption value and no deadline in this document. The quarter records lower revenue year over year on both a three- and six-month basis and a cash balance about half its year-end level.

Confirms DocGo signed a merger agreement to acquire Hicuity Health on August 16, 2026 and that the consideration structure includes a market-capitalization earnout. No consideration amount, closing condition or termination term is stated in the captured text, so nothing about the economics can be read from this row.

A granted second compliance period, not a deficiency notice and not a delisting. The Company says it will evaluate options including initiating a reverse stock split, and notes that at the June 16, 2026 annual meeting stockholders approved an amendment permitting a split at a ratio of 1-for-5, 1-for-6, 1-for-7, 1-for-8, 1-for-9 or 1-for-10 at the Board's sole discretion. No ratio has been chosen and no split has been effected on this report.

The registered ceiling splits into 83,600,000 shares issuable for Ambulnz's outstanding equity securities on an as-converted basis immediately before consummation, and 5,000,000 shares as the maximum issuable under the earn-out. So 5,000,000 of the ceiling is contingent consideration that is not delivered at closing, while the 83,600,000 already absorbs the target's preferred and convertible instruments rather than leaving them to be added later.

The split is fully stated at this version: 83,600,000 shares are issuable in respect of Ambulnz's outstanding equity securities on an as-converted basis immediately before consummation, and 5,000,000 are the maximum issuable under the earn-out provisions. The contingent tranche therefore sits inside the registered ceiling rather than on top of it, and the closing issuance is the smaller figure. The post-combination company collapses to one class of common stock, so the SPAC's two-class structure does not survive the closing.

Three amendments in, the registered amount has not moved and its split is still stated on the face of the table: 83,600,000 shares in respect of Ambulnz's outstanding equity securities on an as-converted basis immediately before consummation, and 5,000,000 as the maximum issuable under the earn-out provisions. The $9.935 is the average of the high and low sales prices of the registrant's Class A Common Stock on June 29, 2021, months old by this filing and used only to compute a fee already paid.

What changed: Q2 2026 10-Q of DocGo Inc. (DCGO), the successor to Motion Acquisition Corp. Revenue was $73,424,719 for the three months ended June 30, 2026 versus $80,417,622 a year earlier, and $148,975,203 for the six months versus $176,450,677. Net loss was $17,992,298 for the quarter (prior year $13,289,893) and $34,692,135 for the six months. Cash and equivalents fell to $25,233,369 from $51,018,657 at December 31, 2025; total assets $186,816,249; accumulated deficit $214,385,203. 98,928,369 shares were outstanding as of August 14, 2026. Why it matters: The filer is the post-combination operating company, not a blank-check shell: there is no trust account, no redemption value and no deadline in this document. The quarter records lower revenue year over year on both a three- and six-month basis and a cash balance about half its year-end level.

What changed: Exhibit 2.1 to an 8-K filed under Motion Acquisition Corp's CIK: an Agreement and Plan of Merger dated August 16, 2026 among DocGo Inc., Ambulnz Holdings, LLC, HH Merger Sub, LLC, Hicuity Health, Inc., and Concord Innovation Fund II, LP (also acting as Shareholder Representative). The portion of the exhibit captured here is the table of contents, which lists a Market Capitalization Earnout (Section 2.6), closing calculations, a post-closing adjustment payment, and dissenting-share and appraisal provisions. Why it matters: Confirms DocGo signed a merger agreement to acquire Hicuity Health on August 16, 2026 and that the consideration structure includes a market-capitalization earnout. No consideration amount, closing condition or termination term is stated in the captured text, so nothing about the economics can be read from this row.(flagged for human review)

What changed: 8-K of DocGo Inc. Item 3.01 (notice of delisting or failure to satisfy a continued listing standard): on July 28, 2026 the Company received a letter from Nasdaq Listing Qualifications granting it an additional 180 calendar days, until January 25, 2027, to regain compliance with the minimum bid price requirement of Listing Rule 5550(a)(2). If at any time before that date the closing bid price is at least $1.00 for a minimum of 10 consecutive business days, Staff will confirm compliance in writing. The report gives no assurance compliance will be regained. Why it matters: A granted second compliance period, not a deficiency notice and not a delisting. The Company says it will evaluate options including initiating a reverse stock split, and notes that at the June 16, 2026 annual meeting stockholders approved an amendment permitting a split at a ratio of 1-for-5, 1-for-6, 1-for-7, 1-for-8, 1-for-9 or 1-for-10 at the Board's sole discretion. No ratio has been chosen and no split has been effected on this report.